Have we undersold lithium for bipolar disorder?

Journal of Clinical Psychopharmacology

Volumn 22, Issue 5, 2002, Pages 445-449

  Pies, Ronald ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; GLYCOGEN SYNTHASE KINASE 3BETA; LAMOTRIGINE; LITHIUM; OLANZAPINE; OXCARBAZEPINE; PLACEBO; PROTEIN BCL 2; VALPROATE SEMISODIUM;

DRUG CHOICE; DYSPHORIA; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOMANIA; LONG TERM CARE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL SOCIETY; NEUROPROTECTION; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; SUICIDE;

BIPOLAR DISORDER; HUMANS; LITHIUM;

EID: 0036785078     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200210000-00001     Document Type: Editorial

References (26)

1. American Psychiatric Association. Practice Guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 2002;159(suppl):1-50.
2. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002;63:288-99.
3. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
4. Strakowski SM, McElroy SL, Keck PE. Clinical efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, eds. Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington DC: American Psychiatric Press, 2000:143-57.
5. Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 1989;98:535-8.
6. Baldessarini RJ, Tondo L. Does lithium treatment still work? Arch Gen Psychiatry 2000;57:187-90.
7. Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-5.
8. Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 2001;178(suppl 41):S184-S90.
9. Baldessarini RJ, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord 2000;61(1-2):13-22.
10. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and practice of psychopharmacotherapy. 2nd ed. Baltimore: Williams and Wilkins, 1997.
11. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-9.
12. Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorder. Arch Gen Psychiatry 2000;57:490-1.
13. Calabrese JR, Bowden CL, Mee-Lee D, et al. Lamotrigine or lithium in the maintenance treatment of bipolar I disorder [abstract NR 236]. Presented at the American Psychiatric Association Annual Meeting, Philadelphia, PA, 2002.
14. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001;62:565-9.
15. Jacobs DG, Jamison KR, Baldessarini RJ, et al. Suicide: clinical/ risk management issues for psychiatrists. CNS Spectrums 2000; 5:32-8.
16. Nierenberg AA, Gray SM, Grandin LD. Mood disorders and suicide. J Clin Psychiatry 2001;62(suppl 25):27-30.
17. Fawcett J, Scheftner W, Clark D, et al. Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study. Am J Psychiatry 1987;144:35-40.
18. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000;61(suppl 9):97-104.
19. Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998;59(suppl 3):95-201.
20. Goldberg JF, Singer TM, Garno JL. Suicidality and substance abuse in affective disorders. J Clin Psychiatry 2001;62(suppl 25):35-43.
21. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001;62:249-55.
22. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48:740-54.
23. Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 2000;61(suppl 9):82-96.
24. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72:879-82.
25. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997;54:9-13.
26. Pies R. The indispensable mood stabilizer. Psychiatric Times 2001;18:38-9